Skip to main content

Table 2 Meta-analysis of ADIPOQ gene polymorphisms and CVD

From: Association between polymorphisms in the adiponectin gene and cardiovascular disease: a meta-analysis

 

+45 T > G

+276 G > T

−11377 C > G

No. studies

Sample size

Per allele risk

I2%

No. studies

Sample size

Per allele risk

I2%

No. studies

Sample size

Per allele risk

I2%

Case/control

OR(95%CI)

P

Case/control

OR(95%CI)

P

Case/control

OR(95%CI)

P

Overall

24

6398/10829

1.22(1.07-1.39)

0.004

74.2

27

8392/18730

0.90(0.83-0.97)

0.007

58.0

20

7835/14023

1.09(1.01-1.17)

0.032

53.6

CHD

17

4685/5881

1.29(1.09-1.52)

0.004

76.9

18

6585/7760

0.89(0.81-0.99)

0.025

65.1

11

5687/7431

1.09(0.99-1.19)

0.090

51.8

Population

               

European origin

12

3751/8269

1.10(0.94-1.27)

0.226

63.1

15

6306/11254

0.95(0.89-1.02)

0.155

33.8

14

5729/10924

1.01(0.94-1.08)

0.880

26.1

East Asian

7

1813/1766

1.19(0.91-1.56)

0.209

82.6

9

1637/6948

0.83(0.68-1.02)

0.074

73.3

6

2106/3099

1.29(1.18-1.42)

<0.001

0

West Asian

3

565/531

2.07(1.33-3.22)

0.001

59.5

2

237/424

0.75(0.41-1.36)

0.337

81.4

0

    

African

2

269/263

1.38(0.79-2.41)

0.257

36.7

1

212/104

0.75(0.53-1.07)

0.110

/

0

    

Study subjects

               

Normal subjects

17

5501/8723

1.20(1.03-1.41)

0.018

78.7

17

6949/13367

0.92(0.84-1.01)

0.082

63.3

12

5897/9627

1.09(1.00-1.19)

0.042

46.6

Subjects with T2D

6

834/1965

1.18(0.90-1.54)

0.222

52.2

8

1261/4667

0.88(0.76-1.02)

0.098

47.0

4

672/1615

0.87(0.75-1.01)

0.07

0

Subjects with MetS

0

    

0

    

2

1084/2085

1.29(1.15-1.46)

<0.001

0

Subjects with RD

1

63/141

2.06(1.10-3.83)

0.023

/

1

63/141

0.64(0.39-1.03)

0.063

/

1

63/141

1.45(0.90-2.32)

0.129

/

Subjects with RA

0

    

1

119/555

0.79(0.57-1.09)

0.151

/

1

119/555

1.01(0.73-1.40)

0.941

/

Sample size

               

More than 1000

5

2911/6409

1.01(0.80-1.28)

0.912

84.5

8

5006/13809

0.93(0.84-1.04)

0.216

65.2

7

5274/9800

1.13(1.03-1.25)

0.014

62.5

Less than 1000

19

3487/4420

1.30(1.12-1.52)

0.001

63.9

19

3386/4921

0.87(0.78-0.97)

0.015

56.0

13

2561/4223

1.04(0.93-1.18)

0.488

49.6

Genotyping method

               

TaqMan

9

3101/4986

1.13(0.94-1.37)

0.188

70.8

10

3362/5571

0.93(0.85-1.01)

0.098

31.6

9

3284/5572

1.00(0.91-1.10)

0.959

33.8

PCR-RFLP

11

2942/5167

1.25(1.01-1.56)

0.043

80.6

9

1958/4516

0.80(0.68-0.94)

0.006

63.1

5

1388/4057

1.19(1.03-1.39)

0.023

43.2

Other

4

355/676

1.44(0.99-2.11)

0.058

54.3

8

3072/8643

0.97(0.83-1.14)

0.728

64.7

6

3163/4394

1.15(0.98-1.35)

0.090

64.0

  1. MAF = minor allele frequency; OR = odds ratio; CI = confidence interval; NA = not available; T2D = type 2 diabetes; MetS = metabolic syndrome; RD = renal disease; RA = rheumatoid arthritis; I2: The inconsistency index for between-studies heterogeneity, where higher values of the index (I2 > 50%) indicate the existence of heterogeneity.